Navigation Links
Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
Date:2/24/2009

NEW YORK, Feb. 24 /PRNewswire/ -- Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss. Drugs of this type include Rosiglitazone and Pioglitazone which have been approved for the treatment of type II diabetes mellitus. Glucose is used by cells in the brain to make energy that they need to live but glucose utilization may be impaired in the brain's of older people and especially those suffering from Senile Dementia or other forms of memory loss. There is growing evidence that this defective brain glucose utilization results from resistance to the action of insulin. Insulin sensitizer drugs such as Rosiglitazone and Pioglitazone help brain cells properly use glucose in individuals whose ability to use it is impaired. Several clinical studies have shown that these insulin sensitizer drugs improve learning and memory.

Dr. Daniel Chain, the Company's Founder & President and one of two inventors of the patent commented: "We are gratified that our seminal ideas concerning the ability of this class of drugs to combat Senile Dementia and other types of memory loss are being tested by GlaxoSmithKline, a major pharmaceutical company." Dr. Chain added: "We are hopeful that this new approach will help combat the devastating consequences of Senile Dementia and also help improve age-related memory loss affecting millions of older people who are not yet demented."

Professor Mike Cawthorne, Director of Metabolic Research, Clore Laboratory at The University of Buckingham (www.buckingham.ac.uk/clore) co-inventor with Dr. Chain and leader of the research team that originally discovered rosiglitazone as a diabetes treatment commented: "If insulin sensitizer drugs such as Rosiglitazone proves affective in clinical trials those results will surely herald an important new therapeutic option to improve the quality of life for people all over the world who suffer from various dementias as well as normal age-related memory loss."

About Mindset BioPharmaceuticals (USA) Inc

MINDSET is a privately held biopharmaceutical company focused on memory loss in Alzheimer's disease, Senile Dementia, Dementia and Age-Related Cognitive Impairment. Mindset has two wholly-owned subsidiaries: Mindset BioPharmaceuticals (Israel) Ltd which has collaborated with Proteome Sciences Plc on project Pro-Tamad to discover and patent proteins which may be used to develop tests for the early diagnosis and treatment of Alzheimer's disease and MindGenix Inc., (www.mindgenix.com) a contract research organization that provides testing in a preclinical model of Alzheimer's disease and related disorders.

For enquiries regarding potential collaboration and/or licensing opportunities regarding our technologies as well as investment in MINDSET, please contact:

    Dr. Daniel Chain, Ph.D.
    President
    Mindset BioPharmaceuticals (USA) Inc
    7 West 18th Street, 9th Floor New York, NY 10011 USA
    Tel: 212-465-0900
    daniel_chain@eartlink.net

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Mindset relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Mindset's product candidates and the sufficiency of Mindset's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Mindset's ability to fund such efforts with or without partners. Mindset undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof.


'/>"/>
SOURCE Mindset BioPharmaceuticals (USA) Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
2. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
3. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
4. XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
5. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
6. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
8. XTL Biopharmaceuticals Implements Restructuring Plan
9. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
10. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
11. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DUBLIN , Feb. 16, 2017 ... the "Synthetic Biology: Global Markets" report to ... ... synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis ... DNA synthesis and assembly, genome editing, bioinformatics and specialty ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... Feb. 16, 2017  Rhythm, a biopharmaceutical ... deficiencies that result in life-threatening metabolic disorders, ... million mezzanine round of financing with existing ... Capital, New Enterprise Associates, Pfizer Venture Investments, ... healthcare investment fund. Rhythm will use the ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):